#24 – Tom Dayspring, M.D., FACP, FNLA – Part V of V: Lp(a), inflammation, oxLDL, remnants, and more
“Use the correct terminology with everything.” –Tom Dayspring
#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain
“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring
#22 – Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins
“Here’s something that’s going to shock you: in an average person, anywhere from 30 to 60 percent of the cholesterol in that LDL particle arrived via an HDL particle.” –Tom Dayspring
#21 – Tom Dayspring, M.D., FACP, FNLA – Part II of V: Lipid metrics, lipid measurements, and cholesterol regulation
“If you learn nothing else today, the first thing is, lipids, for the most part, go nowhere in the human body unless they’re a passenger inside a lipoprotein.” –Tom Dayspring
#20 – Tom Dayspring, M.D., FACP, FNLA – Part I of V: an introduction to lipidology
“Illustrating things made me understand . . . I just learned by illustrating.” –Tom Dayspring
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
#19 – Dave Feldman: stress testing the lipid energy model
“I am on a journey of science, not of advocacy: I’m going to be quite a skeptic.” —Dave Feldman
Transcript — The Drive — Dave Feldman
Transcript of episode 19 of The Drive with Peter Attia, released October 8, 2018.
Statins, Lp(a), and upcoming podcast guests
In other words, statins are not addressing the associated risk in patients with an elevated Lp(a), and this population represents about 25% of those with previous CVD or an indication for statins.
#18 – Richard Isaacson, M.D.: Alzheimer’s prevention
“Anyone with a brain is at risk for Alzheimer’s.” —Richard Isaacson